Coronavirus (COVID-19) antibody response in healthcare staff: What proportion of healthcare staff have COVID-19 antibodies? How long do the antibodies last? Do the antibodies protect against recurring infection?

COVID-19 antibody response in healthcare staff: Prevalence, duration and protection against recurring infection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN15634328

Enrollment

2000

Registered

2020-08-13

Start date

2020-06-02

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) antibody response in healthcare workers Respiratory COVID-19 (SARS-CoV-2 infection)

Interventions

This is an observational study. Participants will receive standard of care treatment for any conditions that arise during the study period. During the initial study visit and follow-up visits, the s

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged =18 years 2. Agrees to complete all aspects of the study

Exclusion criteria

Exclusion criteria: 1. Previously participated in this study on a previous occasion 2. Unable or unwilling to provide informed consent 3. Is a vulnerable person as deemed unfit for the study by the Principal Investigator 4. Current symptoms of COVID-19 or has had COVID-19 symptoms within the last 14 days

Design outcomes

Primary

Measure	Time frame
Prevalence of past immune response to the SARS-CoV-2 virus among healthcare workers, as determined using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline	—

Secondary

Measure	Time frame
1. Duration of SARS-CoV-2 antibodies at follow-up visits in those with a positive antibody test result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months 2. Incidence reduction of SARS-CoV-2 infection during the follow-up time period in the population with a positive SARS-CoV-2 antibody result at enrolment in comparison with a population with a negative SARS-CoV-2 antibody result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months	—

Measure

Time frame

1. Duration of SARS-CoV-2 antibodies at follow-up visits in those with a positive antibody test result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months 2. Incidence reduction of SARS-CoV-2 infection during the follow-up time period in the population with a positive SARS-CoV-2 antibody result at enrolment in comparison with a population with a negative SARS-CoV-2 antibody result at enrolment using measurements of SARS-CoV-2 antibodies from blood samples using the Panbio™ COVID-19 IgG/IgM Rapid Test, with confirmation of positive results using the Abbott Architect® SARS-CoV-2 IgG test, at baseline, 3 and 6 months

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026